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Abstract 
Background: Recent work has perfected yeast-based methods for measuring drug transport by the Plasmodium 
falciparum chloroquine (CQ) resistance transporter (PfCRT).
Methods: The approach relies on inducible heterologous expression of PfCRT in Saccharomyces cerevisiae yeast. In 
these experiments selecting drug concentrations are not toxic to the yeast, nor is expression of PfCRT alone toxic. 
Only when PfCRT is expressed in the presence of CQ is the growth of yeast impaired, due to inward transport of chlo-
roquine (CQ) via the transporter.
Results: During analysis of all 53 known naturally occurring PfCRT isoforms, two isoforms (PH1 and PH2 PfCRT) were 
found to be intrinsically toxic to yeast, even in the absence of CQ. Additional analysis of six very recently identified 
PfCRT isoforms from Malaysia also showed some toxicity. In this paper the nature of this yeast toxicity is examined. 
Data also show that PH1 and PH2 isoforms of PfCRT transport CQ with an efficiency intermediate to that catalyzed by 
previously studied CQR conferring isoforms. Mutation of PfCRT at position 160 is found to perturb vacuolar physiol-
ogy, suggesting a fitness cost to position 160 amino acid substitutions.
Conclusion: These data further define the wide range of activities that exist for PfCRT isoforms found in P. falciparum 
isolates from around the globe.
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Background
Since the discovery of Plasmodium falciparum chloro-
quine (CQ) resistance transporter PfCRT and its role as 
the primary genetic determinant of chloroquine resist-
ance (CQR) in P. falciparum, 53 distinct isoforms of this 
424 amino acid protein have been found to be expressed 
in parasite isolates from around the globe [1–4]. These 
have descended from at least five independent ‘founder 
events’ in four regions: Southeast Asia (SEA), South 
America (SA) (two events), Papua New Guinea (PNG), 
and the Philippines [5, 6], presumably via variable drug 
selection pressure in these regions. Patterns of amino 
acid substitutions and the degree of drug resistance 
conferred by the isoforms segregate in part based on 
their geographic origin. For example, isoforms from SEA 
typically harbour six to eight substitutions and confer 
high-level CQR to SEA P. falciparum isolates, whereas 
SA isoforms tend to harbour four to five substitutions 
and confer more moderate levels of CQR [7, 8]. However, 
even within one geographical region resistance of para-
site isolates to different drugs, as well as other charac-
teristics, can vary considerably, yet the function of many 
PfCRT isoforms expressed in these isolates has not yet 
been studied. Thus, although PfCRT is clearly essential 
for CQR, it is unclear what precise level of CQR, as well 
as what form(s) of multidrug resistance, can be conferred 
by many PfCRT isoforms [3, 4].
Even after the widespread withdrawal of CQ as an 
approved treatment against P. falciparum malaria, 
mutant CQR-conferring PfCRT isoforms have persisted 
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in some regions (especially within SA) [8]. This has been 
attributed to several factors including: PfCRT’s putative 
role in cross-resistance to other quinoline drugs that 
are still in use, the continued use of CQ to treat P. vivax 
malaria in these same regions, acquisition of compensa-
tory genetic alterations that confer unique fitness pheno-
types that require the mutant PfCRT, and most recently, 
the apparent importance of certain PfCRT mutations for 
creating backgrounds in which delayed artemisinin clear-
ance phenotypes can develop more readily [9]. A fifth 
possibility suggested by recent work is that some mutant 
PfCRT isoforms are revertants that do not confer CQR at 
all [4, 10–12], which if validated would have significant 
impact on current drug use policies and might also add 
to the interpretation of data from a variety of earlier field 
based studies (e.g. [13]).
In 2003, Chen and colleagues reported on a puta-
tive CQR founder event in the Philippines [14]. This 
study reported the sequences of PfCRT isoforms ‘PH1’ 
and ‘PH2’, which harbour novel mutations A144T and 
L160Y. Subsequent microsatellite analysis proved that 
these isoforms were in fact new examples of PfCRT 
evolved to harbour the key mutation K76T within a dif-
ferent parasite genetic background [6]. Presence of the 
K76T mutation within PfCRT has until very recently 
been considered ‘diagnostic’ for a CQR phenotype, so it 
is assumed that PH1 and PH2 confer CQR [4, 6]. How-
ever, direct analysis of the  function of these isoforms  is 
required to test this conclusion, particularly since pos-
sible exceptions to CQR status for parasites expressing 
K76T mutant PfCRTs have been noted [10–12].
Globally, PH1 and PH2 PfCRT isoforms are quite 
scarce and to our knowledge have only been found in 
the Philippines. However, for reasons that are not entirely 
clear, they are relatively abundant there as shown in a 
recent screen of 70 Filipino  isolates wherein 33 har-
boured PH1 PfCRT (47 %) and 15 harboured PH2 (21 %) 
[6]. Single-pass drug susceptibility assays on parasite 
isolates expressing PH1 PfCRT indicated low-level CQR 
[13]. However, drug susceptibility measurements with 
parasite isolates (as opposed to more well behaved strains 
established in laboratory culture) often show wider vari-
ability in computed drug IC50 values. Isolates expressing 
PH2 could not be established in culture long enough for 
any drug susceptibility data to be obtained [14]. Thus, it 
remains unclear precisely what drug resistance pheno-
types could be conferred by expression of these PfCRT 
isoforms in different P. falciparum genetic backgrounds.
One possible explanation for why PH1 and PH2 have 
not been seen in other geographic regions is the pres-
ence of an unusual L160Y mutation in these PfCRTs. 
Most amino acid substitutions associated with other 
PfCRT isoforms require only a single base change from 
the wild type coding sequence [e.g., for SA isoforms 
typically: C(tgt)72  →  S(tct or agt), K(aaa)76  →  T(aca), 
A(gcc)144  →  T(tcc), A(gcc)220  →  S(tcc), 
N(aac)326  →  D(gac), I(ata)356  →  L(tta)]. However, 
mutation L160Y in PH1 and PH2 requires two base 
changes [L(ctt)160 → Y(tat)]. This is true even if the par-
asite first acquires silent mutations to create any of the 
other five leucine codons. The only other two base muta-
tions associated with amino acid substitutions in PfCRT 
isoforms are those that confer mutations A144F (found in 
Cam 734 and IsoV PfCRT), A144Y (found in China B, C, 
D PfCRT) and the N75E mutation found in Dd2 PfCRT 
and others from SEA [4]. The A144 mutation is quite rare 
[4] and it is thought that the more common N75E substi-
tution may have arisen via two single base change steps 
(first to create homologous N75D, and then D75E, each 
of which requires only one mutation).
As mentioned, until recently the CQR vs CQS status 
of parasite isolates has often been assigned based on the 
presence of the key PfCRT K76T mutation alone [4]. In 
many cases however, these assignments are made with-
out companion in  vitro drug susceptibility measure-
ments. This practice may have been sufficient when CQ 
was widely used and CQ selective pressure was high, but 
K76T may no longer be a fully reliable predictor of CQR 
[4, 10–12]. For example, in one recent field study 96 % of 
the isolates sequenced were 76T, but only 20 % of these 
demonstrated even moderate resistance to CQ [12]. 
Clearly, it is crucial to monitor the continued evolution 
of PfCRT protein both to inform an understanding of 
its interaction with currently used anti-malarials and to 
assess potential re-introduction of CQ as a regional treat-
ment (perhaps as a companion drug in geographically 
constrained combination therapy). In this paper an initial 
investigation of the function of PfCRT isoforms PH1 and 
PH2, as well as others that show similar mutations rela-
tive to PH1 and PH2, is presented.
Methods
Materials
Yeast DOB were obtained in powder form from MP Bio-
medicals (Solon, OH, USA). Cell culture plastics were 
from BD Falcon (San Jose, CA, USA). Dextrose, galac-
tose, and raffinose were obtained from Sigma (St. Louis 
MO, USA). Glass beads for yeast cell lysis were from B. 
Braun Biotech (Allentown, PA, USA). Anti-V5-HRP 
antibody was from Invitrogen (Carlsbad, CA, USA). 
Mutagenesis reagents were obtained from Agilent (Santa 
Clara, CA, USA). All other chemicals were reagent grade 
or better, were purchased from Sigma (St. Louis MO, 
USA) and used without additional purification.
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Yeast strains
CH1305 (MATa ade2 ade3 ura3-52 leu2 lys2-801) was 
provided by Cannon [15]. ΔVma (MATa leu2Δ0 met15Δ0 
ura3Δ0) and parental strain Saccharomyces cerevisiae 
BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) were from 
the non-essential yeast knockout MATa haploid collection 
which is commercially available through Fisher Scientific. 
Solid and liquid media were prepared as described in Sher-
man et al. [16], and included synthetic complete (SC) media 
lacking one or more specified amino acids, as well as rich 
medium (YPD). Induction of PfCRT protein expression, 
standard yeast growth methods, yeast transfections, and 
other routine methods were as described [3, 4, 17].
Plasmids
The pYES2 backbone containing PfHB3vh, PfDd2vh, 
Pf7G8vh, and PMA-PfHB3vh was constructed previously 
[17] and these were used as template DNA in subsequent 
rounds of multisite-directed mutagenesis via the Agilent 
QUICK Change method to create the various isoforms 
of PfCRT (see Table 1). All constructs were confirmed by 
direct DNA sequencing of the full ‘yeast-optimized’ pfcrt 
gene.
Western blotting
Western blotting was performed as described previously 
[3].
Colony formation assays and quantitative growth analysis
Assays were performed under PfCRT-inducing and 
non-inducing conditions as described [3, 4, 17]. In brief, 
growth under each condition was measured for three 
independent clones in triplicate via back dilution of the 
strain grown under normal non-inducing conditions 
(SD media lacking uracil). Intrinsic growth delays were 
calculated by measuring the time to reach mid-expo-
nential growth under PfCRT-inducing vs non-inducing 
conditions [17]. CQ-dependent growth delay conferred 
by PMAPH1 and PMAPH2 PfCRTs was calculated as 
described previously [17] with an additional correction 
subtracting the small intrinsic growth delay (Fig. 1) con-
ferred by these isoforms.
Yeast vacuole pH measurements
Yeast vacuole pH measurements were performed as 
described elsewhere [18–20]. In brief, cells were grown in 
inducing media (SGR/-URA) to mid-exponential phase. 
They were harvested, washed three times, and resus-
pended to an OD600 of 2.5 in APG media (10  mM argi-
nine, 8 mM phosphoric acid, 2 % galactose, 2 mM MgSO4, 
1 mM KCl, 0.2 mM CaCl2, pH 4) with 50 μM BCECF-AM. 
The solution was then incubated for 20 min at 30 °C, the 
cells were washed three times and resuspended in APG to 
an OD600 of 0.5, and fluorescence emission intensity was 
measured at 535 nm with excitation at 490 nm.
Calibration of probe response was done for each 
experiment involving fresh yeast cultures by suspend-
ing parent cells transformed with empty vector (EV) in 
calibration buffers [50 mM Mes, 50 mM HEPES, 50 mM 
KCl, 50 mM NaCl, 0.2 mM ammonium acetate, 10 mM 
sodium azide, 10 mM 2-deoxy glucose, 50 μM carbonyl 
cyanide m-chlorophenyl hydrazone (CCCP)] at pH set 
from to 4.00 to 7.00 at 1.00 unit intervals [19, 20]. pH 
was determined by referencing sample intensities to the 
calibration curve generated the same day under parallel 
conditions.
Yeast vacuole isolation
Yeast vacuoles were isolated as described previously 
[21], with some modifications. In brief, yeast cultures 
Table 1 Amino acid sequences of PfCRT strains and isolates referenced in this study
Residues mutated relative to wild type are highlighted green. Where multiple CQ IC50 values (nM) were found in the literature, the high and low values are reported 
(Low, High)
Origin Clone/ Isolate 72 74 75 76 144 160 166 220 271 273 326 333 356 371 (nM) Reference
Honduras HB3 C M N K A L I A Q H N T I R 12.3, 33.9 24, 25
Thailand Dd2 C I E T A L I S E H S T T I 48, 404 25, 26
Ghana 7G8 S M N T A L I S Q H D T L R 34, 220 13, 25
Phillipines PH1 C M N T T Y I A Q H D T I R 30.4 13
Phillipines PH2 S M N T T Y I A Q H D T I R N.D. 13
Malaysia KK005 S M N T A L I S Q H D A L R N.D. 27
Malaysia KT052 C M N K T Y V A Q H N T I R N.D. 27
Malaysia KT097 C M N K T Y V A Q N N T I R N.D. 27
Malaysia KT094 S M N T H P I A Q N N T I R N.D. 27
Malaysia KT072 S M N T T Y V A Q H N T I R N.D. 27
Malaysia KT055 S M N T T Y V A Q N N T I R N.D. 27
Malaysia KT066 S M N T T Y V A Q H D T I R N.D. 27
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were grown in SGR-ura to mid-exponential phase and 
cells were harvested at 3000 g for 5 min. The cell pellet 
was resuspended in 50  mL wash buffer [100  mM Tris–
Cl (pH 9.4), 100 mM DTT], cells were incubated at 30 °C 
for 10  min and gently mixed at 2-min intervals. Cells 
were pelleted at 3000  g for 3  min and resuspended in 
15 mL spheroplasting buffer (50 mM KPO4, 0.15 % YPD, 
600  mM sorbitol) via gentle vortexing. Five-hundred 
microliter of zymolase solution [zymolase 20 T (300 mg/
mL) in spheroplasting buffer] was added and gently 
swirled into the cell suspension, cells were incubated 
for 1  h at 30  °C with gentle swirling at 5-min intervals; 
the resulting spheroplasts were transferred to a chilled 
50 mL conical tube and pelleted at 1000 g for 2 min. The 
spheroplast pellet was resuspended in 2.5  mL of 15  % 
ficoll prepared in a 20 mM Pipes (pH 6.8)/200 mM sorbi-
tol solution; 1.5  mg dextran was then swirled into the 
suspension which was then incubated on ice for 5  min 
while swirling every 30  s followed by 2-min incubation 
at 30  °C. Five milliliter of the lysate/15  % ficoll solution 
was pipetted to the bottom of a high-speed (SW-41) cen-
trifuge tube. A ficoll step gradient was pipetted over the 
sample (3.0 mL 8 % ficoll followed by 3.0 mL of 4 % ficoll 
to within about 1 cm of the top of the tube). The tube was 
filled to within 3 mm of the rim with 0 % ficoll solution. 
The tubes were centrifuged at 175,000 rpm for 90 min at 
4 °C and yeast vacuoles were recovered from the interface 
of the 0 and 4 % layers of the gradient. Purified vacuoles 
were stored at −80 °C after adding 50 % glycerol stock (to 
a final concentration of 10 % glycerol) supplemented with 
protease inhibitor cocktail, and snap-frozen over dry ice/
ethanol.
Parasite cell culture
Parasites were grown in sealed flasks at 37  °C in a 5  % 
CO2/5 % O2/90 % N2 atmosphere at 2 % haematocrit in 
RPMI-1640 medium supplemented with 0.5 % AlbuMAX 
II (Gibco/Invitrogen) [22, 23].
Parasite synchronization
Cultures used in this work were routinely synchronized 
every three cycles with a 5 % d-sorbitol treatment which 
lyses mid-stage and late trophozoites as well as schiz-
onts but leaves uninfected red blood cells (RBC), rings, 
Fig. 1 PH1 and PH2 expression is intrinsically toxic to CH1305 yeast. a Colony formation assay in which cells were plated on non-inducing media 
(SD/-URA, top) or inducing media lacking CQ (SGR/-URA, bottom). Expression of PH1 and PH2 PfCRT causes slowed growth in yeast in the absence 
of drug that is substantially mitigated by targeting increased expression to the PM/decreased expression at the vacuole. b Intrinsic growth delay 
calculated by taking the difference in time needed to reach maximal growth rate in inducing vs non-inducing media. Results reported relative to 
control yeast expressing HB3 PfCRT, Baro et al. [17]
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and some early trophozoites unscathed [22]. Multiple 
synchronization treatments successively improve the 
ring: early trophozoite ratio, thus synchronization was 
routinely done three times. For localizing dextran-conju-
gated Oregon green 488 (OGd) to the parasite digestive 
vacuole (DV), methods used previously were followed 
[23].
Single‑cell photometry
Single-cell photometry (SCP) methods for measuring 
parasite DV pH were as described in detail previously 
[22, 23] using custom microscopy systems comprised of a 
Nikon diaphot microscope, a Photometrics Sensys 12-bit 
CCD camera, associated optics, custom perfusion cells, 
and custom dynamic thresholding software.
Spinning disk confocal microscopy
Data acquisition, deconvolution, 3D restoration, and par-
asite DV volume measurements were done as described 
in detail previously [22, 24] using a customized Perkin–
Elmer spinning disk confocal microscope with a 491 nm 
laser line, typically at 200  ms exposure and 35  % laser 
power.
Results
As described in previous work, a rapid method for assay-
ing CQ transport mediated by PfCRT protein expressed 
in growing yeast has been perfected [3, 4, 17]. In this 
method, PfCRT/CQ-dependent growth delay is lin-
early proportional to PfCRT-mediated CQ transport [3, 
17]. Growth delay depends on the expression of PfCRT, 
the concentration of extracelluar CQ, and the magni-
tude of membrane potential across the yeast plasma 
membrane (PM) [3, 4, 17]. Expression of PfCRT alone, 
without including CQ in the yeast growth medium, con-
ferred no change in growth rate and no other change in 
easily measureable yeast characteristics [3, 4, 17]. How-
ever, during the most recent screen of all known, natu-
rally occurring PfCRT isoforms [4] the expression of 
two PfCRT isoforms, PH1 and PH2 (Table  1) [25–28], 
appeared to be intrinsically toxic to growing yeast, mean-
ing expression of the proteins alone, without the pres-
ence of any antimalarial drug, conferred some degree of 
growth inhibition to yeast expressing these PfCRTs (e.g., 
Figure 1a compare lanes 3, 4 bottom panel to lanes 3, 4 
top). Figure 1b further quantifies this growth delay in the 
absence of CQ for yeast expressing unmodified and mod-
ified (see below) PH1 and PH2 vs strains expressing HB3 
and Dd2 PfCRT [3, 4, 17]. Altered levels of PH1 and PH2 
PfCRT expression in these yeast, relative to other PfCRT 
isoforms, does not explain this intrinsic toxicity, since 
expression of these is approximately equal to that of all 
other PfCRT isoforms studied (Fig. 2; see also [4]). These 
results confounded initial attempts to quantify CQ trans-
port catalyzed by PH1 and PH2 PfCRT, since the yeast-
based methods rely on there being no effect of PfCRT 
expression alone [3, 4, 17]. 
PfCRT expressed in these yeast is localized primarily to 
the PM with low levels of expression at other endogenous 
internal membranes, principally the yeast vacuolar mem-
brane [17]. To determine whether PH1 and PH2 PfCRT 
exert their toxicity via PM or vacuolar effects chime-
ras were created wherein PH1 and PH2 PfCRTs created 
using oligonucleotide (Table  2) site—directed mutagen-
esis were fused to the N-terminal leader sequence from 
the yeast plasma membrane H+-ATPase (PMA) (Fig. 3) as 
described previously [17]. Previous work demonstrated 












Fig. 2 V5 Western blot quantifying relative PfCRT expression. Blots 
show approximately equal expression of indicated PfCRT and PMA-
PfCRT isoforms in BY4741 (3 µg yeast membranes, top) and CH1305 
(7 µg yeast membranes, bottom) yeast
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that such PMA-PfCRT fusion proteins remain functional 
and are localized more exclusively to the yeast plasma 
membrane [17], as is now also found for PH1 and PH2 
chimeras (Fig. 4). Chimeras are expressed to similar lev-
els, relative to the unmodified PfCRT isoforms (Fig.  2). 
Colony formation assays for yeast expressing these PH1- 
and PH2-PMA chimeras revealed significant mitigation 
of PH1 and PH2 PfCRT toxicity upon directed expres-
sion to the yeast PM (Fig.  1), indicating that low levels 
of vacuolarly localized PfCRT are the likely cause of the 
observed yeast toxicity. 
Perhaps not coincidentally, previous data showed that 
certain CQR-associated PfCRT isoforms perturb para-
site digestive vacuolar (DV) physiology by decreasing 
DV pH and increasing DV volume [22, 23]. These effects 
are likely to due to perturbations in endogenous DV 
osmolyte traffic upon mutation of PfCRT [23, 29], sug-
gesting that PH1 and PH2 PfCRT toxicity could be linked 
to perturbation of yeast vacuolar physiology caused by 
the small amounts of PfCRT expressed at the yeast vacu-
ole membrane. To investigate this possibility, isoforms 
PH1 and PH2 were expressed in yeast lacking sub-unit 1 
of the vacuolar membrane VMA (BY4741/Δvma1) since 
VMA function is essential for all other vacuolar physiol-
ogy. Interestingly, PH1 and PH2 induction is lethal in a 
Δvma1 yeast background and lethality can be reversed 
by reducing expression within the yeast vacuolar mem-
brane (Fig. 5, right panels; compare PH1 vs PMAPH1 and 
PH2 vs PMAPH2). The same lethal phenotype as well as 
the same mitigation of lethality is observed upon expres-
sion of these PH1/PH2 constructs in seven additional 
VMA sub-unit knockout yeast strains (see “Methods” and 
Table  3). These data suggest that low levels of PH1 and 
PH2 PfCRT vacuolar localization seriously impair residual 
VMA function for the weakened Δvma subunit strains.
Yeast lacking VMA subunits exhibit a well-character-
ized ‘VMA phenotype’ resulting from impaired vacu-
olar acidification. This is typically defined by alkaline 
vacuolar pH and hypersensitivity to Ca2+ (measured as 
impaired growth in the presence of 50  mM CaCl2) [30, 
31]. Alkaline vacuolar pH is an obvious consequence of 
impaired VMA function, and a properly acidified vacu-
ole is required to energize the sequestration of high lev-
els of free Ca2+. To determine if PH1 and PH2 expression 
results in an alkalinized yeast vacuole the probe BCECF-
AM and previously published methods [18–20] were uti-
lized to measure vacuolar pH for BY4741 yeast expressing 
PH1 and PH2 PfCRT (Fig.  6). PH1 and PH2 expression 
Fig. 3 Diagram of PfCRT-vh and PMA-PfCRT-vh open reading frames. 
a Coding region for 424 amino acids of PfCRT (grey), 21 amino acid V5 
epitope (horizontal bars) and 6His tag (black). b 25 N-terminal amino 
acids of PH1 and PH2 PfCRT were replaced with the 111 amino acid 
N-terminal leader sequence from yeast plasma membrane H+-ATPase 
(PMA, white) 
Fig. 4 V5 western blot quantifying relative PfCRT expression in total 
yeast membranes (CM) vs isolated yeast vacuole membranes (Vac) for 
unmodified and and PMA-fused PfCRTs. All lanes contain 3 µg total 
protein. The blot shows that the PMA leader sequence substantially 
reduces PfCRT expression at the yeast vacuolar membrane relative to 
unmodified PfCRT (compare unmodified HB3 PfCRT, left two lanes, 
vs PMA-HB3 PfCRT chimera, middle two lanes). Note that we are 
unable to isolate purified vacuolar membranes for yeast expressing 
unmodified PH1 or PH2 PfCRT, since the intrinsic toxicity conferred by 
these PfCRTs leads to severe growth defects accompanied by serious 
perturbation of vacuolar function (and presumably vacuolar integrity) 
over longer periods of time in culture (see text)
Fig. 5 Colony formation assays for BY4741 and BY4741/Δvma yeast 
expressing the indicated PfCRT isoform, PMA-chimera, or empty vec-
tor (EV). Top panels show equal growth for all strains in non-inducing 
media. Bottom left (BY4741, inducing media) shows intrinsic toxicity 
of PH1 and PH2 expression in the BY4741 parental strain. Bottom right 
(BY4741/Δvma1, inducing media) shows conditional lethality of PH1 
and PH2 expression in BY4741 yeast lacking vma subunit1
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was found to result in more alkaline vacuolar pH relative 
to wild type yeast (transformed with an empty vector) as 
well as yeast expressing canonical CQS (isoform HB3) or 
CQR (isoform Dd2)—associated PfCRTs (Fig.  6). Once 
again, expression of PMA-fusion PH1 and PH2 attenu-
ated the phenotype caused by expression of the unmodi-
fied PH1 and PH2 PfCRTs (Fig. 6).
When control BY4741 and BY4741/Δvma1 yeast are 
compared in the absence vs presence of 50  mM added 
Ca2+ (Fig.  7a vs b, black vs dashed lines respectively) 
Δvma Ca2+ hypersensitivity is readily apparent (com-
pare dashed vs solid lines Fig. 7b vs a). Similarly, BY4741 
yeast expressing PH1 PfCRT (Fig. 7c) or PH2 (not shown) 
showed increased Ca2+ sensitivity (compare dashed vs 
solid line, Fig.  7c). As expected, these sensitivities were 
again reversed by targeting PH1 and PH2 PfCRT locali-
zation to the PM (Fig. 7d). Note the intrinsic toxicity of 
PH1 is apparent by comparing black lines in Fig. 7c vs a, 
as is the mitigation of toxicity by comparing black lines in 
Fig. 7d vs c.
PH1 PfCRT harbours only four amino acid substitutions 
relative to wild type (HB3 sequence, Table 1) and two of 
these (A144T and L160Y) are not found in other isoforms 
(Table  1) [4]. To determine the relative contribution of 
individual PH1 mutations to the intrinsic growth delay 
phenotype a systematic set of site-directed mutants rep-
resenting every combination of the four amino acid sub-
stitutions that distinguish PH1 from HB3 (K76T, A144T, 
L160Y, N326D) were created. Interestingly, results indicate 
that the presence of the L160Y substitution, along with any 
one of the other amino acid substitutions, is required for 
PH1 toxicity (Fig. 8). Any substitution alone, or any other 
combination not involving L160Y, does not cause toxicity.
Interestingly, while this work was being conducted, a 
recent field study carried out in Sabah Malaysia identi-
fied 13 additional PfCRT isoforms [4], with six of these 
harbouring unique mutations A144T, L160Y, or L160P 
(Table 1) [28]. Due to the similarities to PH1 and PH2 iso-
forms these were screened and it was found that the six 
carrying unique mutations are also toxic to yeast, with 
isoform KT094 (L160P mutation; Table 1), conferring the 
highest toxicity yet measured (Fig. 9). The other 7/13 not 
carrying these mutations were not intrinsically toxic and 
are analysed and discussed elsewhere (see [4]). None of 
the 13 PfCRTs found in the isolates sequenced in this study 
[28] was found to harbour an exact PH1 or PH2 PfCRT 
sequence. Each of these new Malaysian isoforms either 
lacks one or more of the mutations contained in isoform 
PH2, or has acquired additional mutations (e.g., I166V 
and/or H273N; Table  1). Isoforms KT072 and KT055, 
which differ from PH2 with respect to a back-mutation 
towards wild type at position 326 (D326N) together with 
additional mutations I166V and H273N (KT072 only) con-
ferred intrinsic growth delays that were slightly less than 
that conferred by PH2 (Fig. 9). It will prove interesting to 
monitor the relative prevalence of KT072/KT055 isoforms 
vs PH2 over time in this region of the globe.
Table 3 Vma subunit knockout strains used in this study
Similar to results for the vma1 strain (see text) PH1 and PH2 expression was found to be synthetically lethal in each yeast strain lacking the designated subunit of yeast 
vacuolar (H+ )-ATPase
Systematic Standard Description
YDL185W VMA1 Subunit A of the V1 peripheral membrane domain of the vacuolar H+-ATPase
YBR127C VMA2 Subunit B of V1 peripheral membrane domain of the vacuolar H+-ATPase
YEL027W VMA3 Proteolipid subunit C of the V0 domain of the vacuolar H+-ATPase
YOR332W VMA4 Subunit E of the V1 peripheral membrane domain of the vacuolar H+-ATPase
YKL080W VMA5 Subunit C of the V1 peripheral membrane domain of vacuolar H+-ATPase
YLR447C VMA6 Subunit D of the V0 integral membrane domain of V-ATPase
YGR020C VMA7 Subunit F of the V1 peripheral membrane domain of vacuolar H+-ATPase
YEL051W VMA8 Subunit D of the V1 peripheral membrane domain of vacuolar H+-ATPase
Fig. 6 Yeast vacuolar pH. Vacuolar pH measured with BCECF-AM as 
described in “Methods” section for BY4741 yeast expressing indicated 
PfCRT isoform or empty vector. Asterisk indicates p value <0.05 vs 
empty vector
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The galactose-inducible PfCRT expression system 
can be used to measure PfCRT-mediated CQ trans-
port, which has obvious direct significance with respect 
to parasite drug resistance. But, as mentioned above, 
the intrinsic toxicity of PH1 and PH2 in yeast would 
not allow unbiased measurement of a CQ transport 
phenotype. Therefore, growth delay for PMAPH1 and 
PMAPH2 chimera-expressing yeast was measured in the 
presence vs absence of CQ (Fig. 10) in order to calculate 
Fig. 7 CaCl2 inhibits growth of Δvma1 and PH1-expressing yeast. BY4741/EV (a), BY4741Δvma1/EV (b), BY4741/PH1 (c), BY4741/PMAPH1 (d) 
growth in the presence of 0 mM (black trace) or 50 mM CaCl2 (dashed trace). Yeast strains were grown in media ± added 50 mM CaCl-2 in 96 well 
plates monitored by a Tecan automated plate reader as described [3, 4, 17]
Fig. 8 Intrinsic growth delays conferred by artificial (non natural) 
PfCRT isoforms with partial combinations of mutations that distin-
guish HB3 from PH1 PfCRT. Isoforms are named on the basis of muta-
tions they harbour relative to HB3 PfCRT where A = K76T, B = A144T, 
C = L160Y, D = N326D. Growth delays reported relative to control 
yeast expressing HB3 PfCRT
Fig. 9 Intrinsic growth delay for yeast expressing the indicated PfCRT 
isoform
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the transport of CQ mediated by these isoforms [3]. CQ 
transport was found to be intermediate to that catalyzed 
by CQR-conferring isoforms 7G8 and Dd2 (Fig. 10), pre-
dicting lower levels of CQR in PH1 and PH2—expressing 
P. falciparum.
To further test these conclusions parasite lines C8PH1 
and C10PH2 were examined. These are gene edited deriva-
tives of P. falciparum strain GC03 expressing PH1 and 
PH2 PfCRT recently created in the Fidock laboratory 
and have been reported on in more detail elsewhere [32]. 
Consistent with CQ transport mediated by PH1 and 
PH2 (Fig. 10) the gene-edited strains show intermediate 
levels of drug resistance ([32], D Fidock, pers. comm.). 
Because of the disruption to yeast vacuolar physiology 
caused by these isoforms potential changes to P. falcipa-
rum DV physiology for C8PH1 and C10PH2 were exam-
ined. Such changes might also help explain why these 
isoforms are relatively rare outside of the Philippines. 
Although the precise endogenous function of PfCRT 
remains unknown, hypotheses include ion, amino acid, 
glutathione and peptide transport from the DV [1, 29, 
33–35]. Expression of CQS vs CQR isoforms of PfCRT 
have been shown to have different effects on DV pH and 
DV volume, as well as the accumulation of peptide frag-
ments upon haemoglobin (Hb) proteolysis in some stud-
ies [22, 23, 29, 36]. Using previously published methods 
involving dextran-nerf exclusively entrapped within the 
DV [22, 23] DV pH and DV volume for PH1 and PH2 
gene edited strains were measured to determine if these 
isoforms affected DV physiology in a manner distinct 
from control gene edited strains C2GC03 and C4Dd2, which 
harbour wild type and SEA CQR-conferring PfCRT iso-
forms, respectively. Interestingly, and although other 
transfectants expressing CQR PfCRT isoforms Dd2 and 
7G8 were previously found to have more acidic DV pH 
[23], mild, but statistically significant alkalinization 
of DV pH for transfectant strains expressing PH1 and 
PH2 PfCRT (Table 4) was measured. Also in contrast to 
strains expressing other CQR-conferring PfCRTs [22], 
DV volume was found to be slightly smaller than DV vol-
ume for control transfectants expressing CQS-associated 
(HB3) PfCRT (Table 4).
Discussion
When taken together, data in this paper, along with other 
recent work [3, 4, 17], shows that PfCRT drug transport 
activity does not correlate with levels of CQR found in 
the cognate strain or isolate expressing that PfCRT iso-
form. This indicates that other factors, or other functions 
of PfCRT, complement the CQR phenotype conferred 
by PfCRT-mediated CQ transport. Previous data [4] 
also show that some PfCRT isoforms predicted to con-
fer CQR via sequence analysis (e.g., the presence of K76T 
substitution) do not catalyze heightened CQ transport at 
all and are thus unlikely to confer CQR, consistent with 
other reports [10–12]. Data in this paper further suggest 
that certain combinations of mutations in K76T PfCRTs 
(particularly those involving residues 144 and 160) very 
significantly effect CQ transport.
In all previous experiments analysing PfCRT isoform 
function in yeast, neither the presence of external CQ 
alone or PfCRT expression alone conferred any signifi-
cant change in yeast growth rates, whereas the presence 
of both PfCRT and external CQ leading to increased 
inward transport of toxic CQ dramatically slowed yeast 
growth [3, 17]. In contrast, eight isoforms of PfCRT that 
harbour an unusual mutation at residue 160 (two from 
Philippines, six from Malaysia) are now found to be 
Fig. 10 PfCRT induced growth delay in the presence of 16 mM CQ 
and calculated CQ transport catalyzed by PMA chimeras, vs previously 
measured transport for Dd2 and 7G8 PfCRT. Growth delays for PMA-
PH1 and PMA-PH2 were measured as in Baro et al. [3] and converted 
to CQ transport using previously generated calibration curves as in 
Baro et al. [3]
Table 4 Digestive vacuole volume and  pH of  transfected 
parasite lines
Values represent the average of three independent experiments per line
Parasite line PfCRT Isoform DV Vol (µm3) SEM DV pH SEM
GCO3C2 HB3 2.03 0.10 5.75 0.01
GCO3C4 Dd2 2.80 0.11 5.31 0.02
GCO3C8 PH1 1.61 0.04 5.84 0.04
GCO3C10 PH2 1.74 0.03 5.81 0.03
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intrinsically toxic to yeast, since they slow growth when 
expressed even in the absence of CQ. The intrinsic yeast 
toxicity of these unusual mutant isoforms is the result 
of an alteration or dysregulation of the yet incompletely 
described endogenous function of PfCRT. Thus, CQ 
transport could not be easily quantified for the interest-
ing PH1 or PH2 PfCRT isoforms in their unmodified 
form. Nonetheless, transport for PMAPH1 and PMAPH2 
chimeras was quantified (Fig. 10) and showed that these 
isoforms transport CQ with an efficiency that is inter-
mediate to transport found previously for CQR isoforms 
7G8 and Dd2. This is consistent with previous CQ trans-
port results for these same isoforms expressed in oocytes 
[37] and with initial measurement of the levels of CQR 
conferred by these isoforms in P. falciparum transfect-
ants [32].
Further experiments indicated that targeted expression 
of PH1 and PH2 PfCRT to the yeast PM substantially 
reduced the toxicity of these isoforms (Figs.  1, 4). This 
suggested that the bulk of PH1 and PH2 PfCRT toxicity 
is levied from a different localization. Given that PfCRT 
is being over-expressed in this yeast model system and 
that the vacuolar membrane harbours the second most 
abundant amount of PfCRT [17], it was suspected that 
PH1 and PH2 PfCRT within the vacuolar membrane 
caused the intrinsically toxic phenotype. The lethality of 
PH1 and PH2 expression in Δvma yeast strains provided 
additional evidence for this hypothesis, as did observed 
elevated yeast vacuolar pH and increased yeast sensitiv-
ity to Ca2+ (hallmarks of a dysregulated yeast vacuole), 
all of which were then reversed for the PMAPH1 or 
PMAPH2 chimeras. Analysis of a systematic set of arti-
ficial mutants harbouring every possible combination of 
PH1 mutations indeed indicated that it is mutation at 
L160 (observed only in these eight out of 53 total known 
PfCRT isoforms) that is obligate for conferring the intrin-
sic toxicity. Interestingly however, mutation L160Y has a 
very small effect on PfCRT function when present alone 
and only creates an intrinsically toxic PfCRT when paired 
with any one of the other three PH1 mutations (Fig. 9). 
Analysis of isoform KT094 provided additional evidence 
pointing to the unique importance of residue 160. KT094 
harbours a L160P mutation and a wild type 144A yet 
confers the largest growth delay of any of the natural iso-
forms yet examined.
Field studies measuring the prevalence of wild type 
vs CQR-conferring PfCRT isoforms have found that in 
some areas where CQ pressure has been removed, the 
percentage of parasites harbouring wild type PfCRT has 
increased relative to parasites harbouring Old World 
CQR-associated isoforms (e.g., Dd2 and FCB isoforms of 
SEA origin), but not relative to New World CQR isoforms 
(e.g., 7G8 and PNG4 from SA and PNG) [8, 38–40]. 
This phenomenon has been cited as evidence for a fit-
ness cost associated with isoforms that have amino acid 
residue 72–76 sequence  =  CVIET, but not  =  SVMNT 
(Table  1) [4]. The spread of SVMNT isoforms over the 
past 20  years provides additional evidence in support 
of this hypothesis. PH1 and PH2 isoforms represent a 
unique case in that they indeed more closely resemble 
New World isoforms, and are common within the Philip-
pines, but nonetheless have not yet spread geographically 
beyond the  Philippines. In fact, several field studies in 
Cambodia, Vietnam and China have been devoted to the 
search for mutations A144T and L160Y and while these 
studies have led to the discovery of several new isoforms 
with novel mutations at residue 144 (A144F, A144Y), no 
isoforms harbouring mutations at residue 160 have been 
found [10, 41, 42]. In contrast, a very recent field study 
from Sabah, Malaysia, which shares a maritime border 
with the  Philippines, reported the isolation of six para-
sites expressing PfCRT isoforms with mutations to resi-
due 160 (Table 1) [28]. However, none of these isoforms 
is an exact match to PH1 or PH2 PfCRT. Two of these 
isoforms (KT055 and KT072) conferred less yeast toxic-
ity relative to PH2 PfCRT from which they are probably 
derived. This may provide additional evidence that PH1 
and PH2 PfCRT-bearing parasites are less stable or can-
not thrive outside Filipino drug use practices without the 
acquisition of compensatory mutations (e.g., I166V and 
H273N). It is worth noting that these putative compen-
satory mutations are also present in PfCRT orthologues 
from other malaria species for which no link between 
PfCRT mutation and CQR has yet been established. 
Mutation I166V is found in wild type P. chabaudi and P. 
yoelii PfCRTs and mutation H273 N is found for PfCRT 
expressed in P. vivax and P. knowlesi. It is possible that 
these residues are required to restore or better maintain 
endogenous physiological PfCRT function in the pres-
ence of other CQR-conferring mutations.
Consistent with perturbations in yeast vacuolar physiol-
ogy, results from transfected P. falciparum lines harbour-
ing PH1 and PH2 PfCRT reveal that expression of either 
isoform also alters pH and reduces DV volume for mid 
stage trophozoites (Table 4). Previous studies have shown 
that P. falciparum-transfected lines expressing Dd2 or 
7G8 PfCRT have increased DV volume [22] and analysis 
of PfCRT homologue TgCRT from Toxoplasma gondii 
demonstrated that reduced TgCRT expression yielded an 
increase in the volume of that parasite’s vacuole (an inter-
nal acidic organelle similar to the DV) [43]. It has been 
suggested that the increased volume phenotype in these 
examples is indicative of impaired or reduced normal 
physiological function of the PfCRT resulting from either 
eight amino acid substitutions required for CQR (Dd2) or 
decreased levels of TgCRT. In theory, reduced transport 
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of PfCRT’s physiological substrate (possibly Hb-derived 
peptides [29]) would result in substrate accumulation 
within the DV and a concomitant increase in DV volume. 
By the same reasoning then, perhaps upregulated endog-
enous transport function by PH1 and PH2 PfCRT is 
reducing internal PfCRT substrate concentration relative 
to wild type such that DV volume would then decrease. 
Consistent with this hypothesis, bioinformatic analysis of 
PfCRT homologues places mutations A144T and L160Y 
at sites predicted to be important for translocation and 
binding of substrate, respectively [44]. Further studies are 
required to test this idea by determining if PH1 and PH2 
isoforms alter the peptide accumulation phenotype asso-
ciated with Dd2 PfCRT [29]. However, additional data 
showing yeast alkaline vacuolar pH due to PH1 and PH2 
predicts that Hb-derived peptides are unlikely to be the 
only substrate for PfCRT, since these do not exist in the 
yeast vacuole. The results of Lewis et al. [29] actually do 
not require that PfCRT transport peptides at all. Alterna-
tively, since the proteases that cleave Hb to create these 
peptides are highly pH dependent, altered DV pH caused 
by mutation of PfCRT could also produce the results seen 
by Lewis et  al. [29]. This reasoning is attractive since it 
does not envision that PfCRT recognizes a wide variety 
of structurally divergent peptides, dipeptides, or amino 
acids. Presumably alterations in yeast vacuole pH caused 
by PH1 and PH2 PfCRT are due to altered ion transport 
as also proposed for other mutant PfCRTs [22, 35, 45, 46], 
perhaps heightened outward movement of H+ relative to 
HB3 and Dd2 PfCRT.
Conclusions
Recently, CQ transport for 45 of the 53 naturally occur-
ring isoforms of PfCRT has been measured and found 
to have a wide range of activities that predict a range of 
CQ sensitivities for P. falciparum isolates expressing 
these isoforms [3, 4, 17]. In this work the remaining eight 
known, naturally occurring, isoforms of PfCRT (all of 
which harbour a substitution at residue 160) were exam-
ined. Along with data in this paper, there is also evidence 
from other studies that PfCRT residues at or near posi-
tion 160 are critical for proper balance between parasite 
fitness characteristics and drug resistance [48–50]. The 
eight isoforms studied here are unusual not only in their 
pattern of amino acid substitutions, but also because they 
show varying levels of intrinsic toxicity when expressed 
in yeast, most likely through significant disruption of 
yeast vacuolar physiology. This behaviour is distinct from 
that of the other 45 naturally occurring PfCRT isoforms 
[3, 4], yet further highlights the role that PfCRT plays 
in maintaining critical vacuolar properties [22, 29, 48]. 
Previously, acidic DV pH and larger DV volume have 
been found for some CQR strains expressing certain 
CQR—associated mutant PfCRT isoforms [23, 24], but 
additional results in this paper suggest that other CQR—
associated mutant PfCRTs can exert reciprocal effects on 
these parameters. As previously suggested these physi-
ologic perturbations of DV pH and volume likely add 
together with CQ transport catalyzed by PfCRT to fur-
ther affect levels of CQR [33]. Lower DV pH can indeed 
promote CQR by leading to aggregation of the CQ target 
(free DV haem) as previously suggested [47] and elevated 
DV pH would be predicted to add to CQR by lowering 
DV concentrations of CQ via the predictions of weak 
base partitioning [51]. More work defining the magni-
tude of these physiological changes in other transfectants 
expressing other PfCRT isoforms, and in calibrating the 
precise contributions that they make to CQR, is needed 
to further test these theories.
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